No Data
How Peter Marks' FDA Departure Is Impacting Pharma, Biotech Stocks
Express News | Taysha Gene Therapies Down 10.9%, Solid Biosciences Down 7.2%, US-Listed Shares of CRISPR Therapeutics Down 3.8%, Beam Therapeutics Down 3.2% Premarket
Express News | Shares of Gene Therapy Makers and Developers Fall Premarket After Report That FDA Official Peter Marks Has Resigned
BofA Securities Upgrades Beam Therapeutics(BEAM.US) to Buy Rating, Maintains Target Price $42
Beam Upgraded to Buy at BofA Securities on Recent Genetic Condition Treatment
Sector Update: Health Care Stocks Steady Premarket Friday
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
It feels like being online all day long, pay attention to resting.
